Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bristol-Myers Squibb and Medarex have reported that their global development and commercialization collaboration agreement for melanoma treatment candidate MDX-010 has now become effective.
Subscribe to our email newsletter
The agreement, previously announced by both companies on November 8, 2004, became effective after all conditions were satisfied, including expiration of the waiting period required under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
Under the collaboration agreement, Bristol-Myers Squibb and Medarex plan to jointly develop MDX-010, a fully human antibody investigational product targeting the CTLA-4 receptor, which is currently in phase III clinical development for the treatment of metastatic melanoma.
Medarex will receive an initial cash payment of $50 million, of which $25 million will be for a purchase of Medarex’s common stock by Bristol-Myers Squibb. In addition, Medarex could receive up to $205 million if all regulatory milestones are met, and up to $275 million in sales related milestones.
Medarex has an option to co-promote and share profits with Bristol-Myers Squibb in the US and Bristol-Myers will receive an exclusive license outside the US and will pay royalties to Medarex on any commercial sales.